Characteristics of the CCR5 Antagonist | NIH

Updated

Jun. 03, 2021

Reviewed

Jun. 03, 2021

Appendix B: Drug Characteristics Tables

Characteristics of the CCR5 Antagonist

Appendix B, Table 8. Characteristics of the CCR5 Antagonist
Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations^a	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events^b
Maraviroc (MVC) Selzentry	Selzentry: 150-mg and 300-mg tablets	Selzentry: MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r) MVC 300 mg PO twice daily when given with NRTIs, T-20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor) Take MVC without regard to meals.	14–18 hours	CYP3A4 substrate	Abdominal pain Cough Dizziness Musculoskeletal symptoms Pyrexia Rash Upper respiratory tract infections Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions Orthostatic hypotension, especially in patients with severe renal insufficiency
^a For dose adjustment in patients with hepatic insufficiency, see Appendix B, Table 11. ^b Also see Table 20. Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; T-20 = enfuvirtide; TPV/r = tipranavir/ritonavir

Appendix B: Drug Characteristics Tables

Characteristics of the CCR5 Antagonist

Appendix B, Table 8. Characteristics of the CCR5 Antagonist
Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations^a	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events^b
Maraviroc (MVC) Selzentry	Selzentry: 150-mg and 300-mg tablets	Selzentry: MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r) MVC 300 mg PO twice daily when given with NRTIs, T-20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor) Take MVC without regard to meals.	14–18 hours	CYP3A4 substrate	Abdominal pain Cough Dizziness Musculoskeletal symptoms Pyrexia Rash Upper respiratory tract infections Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions Orthostatic hypotension, especially in patients with severe renal insufficiency
^a For dose adjustment in patients with hepatic insufficiency, see Appendix B, Table 11. ^b Also see Table 20. Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; T-20 = enfuvirtide; TPV/r = tipranavir/ritonavir

Download Guidelines

Section OnlyPDF (188.17 KB)
Full GuidelinePDF (3.89 MB)
Recommendations OnlyPDF (292.88 KB)
Tables OnlyPDF (1.68 MB)